Cited by Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein

Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies DOI

Hugues Fausther‐Bovendo,

George Babuadze,

Teodora Ivanciuc

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 637 - 637

Published: March 5, 2025

Background: Monoclonal antibodies (mAbs) are potent treatment options for infectious diseases. The rapid isolation and in vivo validation of therapeutic mAb candidates, including cocktails, essential to combat novel or rapidly mutating pathogens. selection production candidates sufficient amount quality preclinical studies a major limiting step the development pipeline. Methods: Here, we developed method facilitate screening mAbs mouse models. Four conventional were transformed into single-chain variable fragments fused fragment crystallizable (Fc) region human IgG1 (scFv-IgG). These scFv-IgG expressed individually as cocktail vitro mice following transfection hydrodynamic delivery corresponding plasmids. Results: This induced high expression all provided protection two murine infection Conclusions: study highlights benefits this approach rapid, low-cost candidates.

Language: Английский

Citations

Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics DOI

Vaishali Verma,

N. D. Sinha,

A. Raja

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 9, 2025

Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance emergence new strains. In this context, novel therapeutic modalities essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for treatment several diseases, nanobodies derived from heavy chain-only have emerged promising "nanoscale warriors" against infections. Nanobodies possess unique structural properties that enhance their ability recognize diverse epitopes. Their small size also imparts properties, improved bioavailability, solubility, stability, proteolytic resistance, making them an ideal class therapeutics review, we discuss role antivirals various Techniques developing nanobodies, delivery strategies covered, challenges opportunities associated use therapies discussed. We offer insights into future nanobody-based research support managing

Language: Английский

Citations

Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry DOI

Jun Zheng,

Qiuxia Pang,

Zhaoying Fu

et al.

ACS Omega, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The enters cell through binding to corresponding receptor angiotensin-converting enzyme (ACE2) on host membrane with spike protein (S protein) its envelope; thus, we can design inhibitors that bind S block entry into cells. Aptamers are single stranded DNA or RNA molecules form specific three-dimensional structures and their target high affinity specificity thus promising candidates for inhibitors. This paper reviews replication cycle mechanisms SARS-CoV-2 as well preparation principle characteristics aptamers, features discussion advantages using aptamers prevent from infecting cells, finally summarizes research progress in protein-blocking aptamers.

Language: Английский

Citations

Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein DOI

Chen Liu, Hadiatullah Hadiatullah, Zhiguang Yuchi

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 281, P. 136403 - 136403

Published: Oct. 9, 2024

Language: Английский

Citations